// App-Quantinova.ai

132 : Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Ulka N. Vaishampayan

Principal Investigators

  • Marianne Keessen

  • Neal D. Shore

  • Elisabeth I. Heath

  • Robert Dreicer

  • Tomas Buchler

  • Pter Ferenc rkosy

  • Tibor Csoszi

  • Pawel Wiechno

  • Evgeny Kopyltsov

  • Denis Kholtobin

  • Aleander Nosov

  • Sergei Varlamov

  • Nicholas J. Vogelzang

Medical Centers

  • University of Michigan, Ann Arbor, MI

  • Teva Pharmaceuticals, Amsterdam, Netherlands,

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA

  • Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

  • Debrecen Institute of Oncology, Debrecen, Hungary

  • Hetenyi G Korhaz, Szolnok, Hungary

  • Klinika Nowotworów Układu Moczowego Centrum Onkologii, Warsaw, Poland

  • State Institution of Healthcare, Omsk, Russian Federation

  • CJSC Medical Center "AVICENNA", Novosibirsk, Russian Federation

  • NN Petrov Research Institute of Oncology, St Petersburg, Russia

  • Altai Regional Cancer Center, Barnaul, Russia

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

Locations

  • United States

  • Netherlands

  • Czech Republic

  • Hungary

  • Poland

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Prednisone

  • Docetaxel

  • Ritonavir

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT04028388

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved